Shukra Pharmaceuticals Ltd Completes Listing on NSE; Stock Continues Trading on BSE
Shukra Pharmaceuticals Limited has successfully listed its equity shares on the Main Board of the National Stock Exchange of India Limited (NSE). The listing and admission to dealings on NSE took effect starting Friday, August 14, 2026. This event marks a significant step for the pharmaceutical company in expanding its market presence.The company's equity shares will continue to be listed and traded concurrently on BSE Limited (BSE), maintaining dual-listing status across both exchanges.
Key trading details for Shukra Pharmaceuticals Limited on NSE are as follows:
| Detail | Information |
|---|---|
| Company Name | Shukra Pharmaceuticals Limited |
| NSE Trading Symbol | SHUKRAPHAR |
| ISIN | INE551C01044 |
| Market Segment | Main Board - Equity |
The company disclosed that the base reference price used for today's trading session on NSE was determined based on the closing market price of its shares on BSE on August 13, 2026.
The management views this dual listing as a major milestone aimed at enhancing liquidity, expanding the investor base, and maximizing stakeholder value for Shukra Pharmaceuticals Limited. The continued presence on both exchanges underscores the company's commitment to broad market accessibility.
SHUKRAPHAR Stock Price Movement
Shares of Shukla Pharmaceuticals Limited are slipping as of 12:16 PM in live trading, shedding 1.7% or ₹0.70 to trade at ₹40.55. The stock has seen significant activity with a volume of 634,800 shares traded so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.